Met Life Investment Management, LLC Viking Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 6,629 shares of VKTX stock, worth $354,121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,629
Previous 6,759
1.92%
Holding current value
$354,121
Previous $358,000
17.04%
% of portfolio
0.0%
Previous 0.0%
Shares
46 transactions
Others Institutions Holding VKTX
# of Institutions
474Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$543 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$322 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$250 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$113 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$100 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.1B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...